Functional small-diameter neovessels created using endothelial progenitor cells expanded ex vivo
Sunjay Kaushal1, 2, Gilad E. Amiel4, Kristine J. Guleserian1, Oz M. Shapira6, Tjorvi Perry1, Fraser W. Sutherland1, Elena Rabkin5, Adrian M. Moran3, Frederick J. Schoen5, Anthony Atala4, Shay Soker4, Joyce Bischoff2
& John E. Mayer Jr1
1
Department of Cardiac Surgery, Children's Hospital, Boston, Massachusetts, USA
2
Department of Surgery, Children's Hospital, Boston, Massachusetts, USA
3
Department of Cardiology, Children's Hospital, Boston, Massachusetts, USA
4
Department of Urology, Children's Hospital, Boston, Massachusetts, USA
5
Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts, USA
6
Department of Cardiothoracic Surgery, Boston University School of Medicine, Boston, Massachusetts, USA
Arterial conduits are increasingly preferred for surgical bypass because of inherent functional properties conferred by arterial endothelial cells, especially nitric oxide production in response to physiologic stimuli. Here we tested whether endothelial progenitor cells (EPCs) can replace arterial endothelial cells and promote patency in tissue-engineered small-diameter blood vessels (4 mm). We isolated EPCs from peripheral blood of sheep, expanded them ex vivo and then seeded them on decellularized porcine iliac vessels. EPC-seeded grafts remained patent for 130 days as a carotid interposition graft in sheep, whereas non-seeded grafts occluded within 15 days. The EPC-explanted grafts exhibited contractile activity and nitric-oxide−mediated vascular relaxation that were similar to native carotid arteries. These results indicate that EPCs can function similarly to arterial endothelial cells and thereby confer longer vascular-graft survival. Due to their unique properties, EPCs might have other general applications for tissue-engineered structures and in treating vascular diseases.
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated
